FOSUN PHARMA reported first-half 2026 revenue of RMB 20.38 billion, a 4.90 % year-on-year increase. Revenue from Innovative Drugs rose 13.84 % to RMB 4.91 billion, lifting the segment’s share of pharmaceutical manufacturing sales to 33.35 %.
Profit attributable to shareholders edged up 1.15 % to RMB 1.72 billion, while net profit margin slipped 0.26 percentage points to 10.55 %. Operating cash flow strengthened 13.59 % to RMB 2.42 billion.
Gross margin improved 1.63 percentage points to 49.51 % on stable product mix and cost control. R&D expenditure jumped 25.66 % to RMB 3.25 billion, equal to 15.88 % of total revenue; 81.61 % of R&D spending targeted innovative pipelines.
Segment performance showed:
• Pharmaceutical Manufacturing: revenue RMB 14.73 billion, up 6.59 %; segment profit RMB 1.70 billion, up 6.99 %. • Medical Devices & Diagnosis: revenue RMB 1.86 billion, down 4.81 %; segment loss narrowed to RMB 22 million. • Healthcare Services: revenue RMB 3.74 billion, up 4.07 %; segment loss widened to RMB 207 million.
Overseas markets contributed RMB 6.38 billion, up 16.45 % and representing 31.30 % of group revenue. Chinese mainland sales were RMB 13.99 billion, flat year-on-year.
Total assets reached RMB 125.39 billion, while interest-bearing debt increased to RMB 35.79 billion, bringing the gearing ratio to 28.55 %. Cash and bank balances stood at RMB 13.62 billion.
During the period the group launched seven innovative drugs with 20 new indications and filed four NDAs. Key approvals included the domestic launch of luvometinib tablets for pediatric LCH and pertuzumab biosimilar clearances in China and the EU. The company also accelerated AI integration across R&D, clinical and manufacturing processes, rolling out over 25 production-stage AI projects.
Management reaffirmed its focus on “innovation-driven, deep globalization”, emphasizing pipeline advancement in oncology, immunology and neurodegeneration, continued expansion of overseas revenue, and disciplined cost control for the remainder of 2026.